TMED — EGF Theramed Health Income Statement
0.000.00%
Last trade - 00:00- CA$1.51m
- CA$1.60m
- 12
- 15
- 56
- 17
Annual income statement for EGF Theramed Health, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 21.4 | 0.82 | 1 | 0.606 | 0.297 |
| Operating Profit | -21.4 | -0.82 | -1 | -0.606 | -0.297 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.6 | -0.744 | -1.36 | -0.643 | -0.296 |
| Net Income After Taxes | -21.6 | -0.744 | -1.36 | -0.643 | -0.296 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -21.6 | -0.974 | -1.35 | -0.623 | -0.269 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -21.6 | -0.974 | -1.35 | -0.623 | -0.269 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -18.8 | -1.34 | -0.627 | -0.062 | -0.024 |